Acute Myeloid Leukemia (AML) – Epidemiology Insights and Disease Burden Report – 2020 To 2040

Acute Myeloid Leukemia (AML) Epidemiology Insights and Disease Burden

Thelansis’s “Acute Myeloid Leukemia (AML) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

Acute Myeloid Leukemia (AML) Overview

Acute myeloid leukemia (AML) is an aggressive clonal hematopoietic malignancy arising from myeloid progenitor cells, characterized by the rapid accumulation of immature blast cells in the bone marrow. Somatic mutations in FLT3, NPM1, IDH1, IDH2, and TP53 alongside cytogenetic aberrations guide European LeukemiaNet risk stratification and subsequent treatment intensity. Intensive induction chemotherapy remains the frontline standard for fit patients, followed by allogeneic stem cell transplantation for intermediate and adverse risk profiles, while venetoclax combined with hypomethylating agents serves as the care standard for unfit cohorts. Targeted options have fundamentally transformed molecular sub-segments. Frontline maintenance features FLT3 inhibitors like midostaurin or quizartinib alongside targeted IDH inhibitors (ivosidenib, enasidenib). Crucially, the relapsed or refractory setting has transitioned with the formal approvals of oral menin inhibitors. This targeted class includes Revuforj (revumenib) indicated for KMT2A-rearranged and NPM1-mutated presentations, alongside the once-daily agent Komzifti (ziftomenib) for refractory NPM1-mutated cohorts. Both menin inhibitors require strict monitoring for class-specific differentiation syndrome. Multidisciplinary care and rigid measurable residual disease (MRD) tracking are essential to optimize long-term survival.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
  • Global findings
  • G8 findings
  • Regional findings
  • Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)